HIV Antivirals Market

Market Insights on HIV Antivirals covering sales outlook, demand forecast & up-to-date key trends

HIV Antivirals Market by Product, Distribution Channel & Region - Forecast 2022 - 2032

HIV Antivirals Market Outlook (2022-2032)

[300 Pages Report] The global HIV antivirals market is set to reach a valuation of US$ 30.6 Bn in 2022, and register a CAGR of 4.4% during the forecast period (2022-2032). According to a recent study, fixed-dose combinations (FDCs) are leading the HIV antivirals market with a share of over 83% in 2021.

Market Outlook:

Data Points	Market Insights
HIV Antivirals Market Value 2021	US$ 29.4 Bn
Market Value 2022	US$ 30.6 Bn
Market Value 2032	US$ 47.0 Bn
CAGR 2022-2032	4.4%
Market Share of Top 5 Countries	64.8%

The demand for HIV antivirals is projected to surge with increasing access to effective HIV diagnosis, treatment, prevention, and care. It makes HIV infection a manageable chronic health condition such as cancer and tuberculosis, which enables people living with HIV to lead healthy and long lives.

The HIV antivirals market is poised to expand on the back of rising awareness about HIV causes, symptoms, and available treatment options. There are various awareness programs organized by the U.S. Department of Health & Human Services for creating awareness regarding HIV and its testing.

For instance, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) observe the day 18th May as HIV Vaccine Awareness Day. This is to show gratitude towards the community members, volunteers, healthcare professionals, and scientists working together to find a safe and effective preventive HIV vaccine.

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

Sales Analysis of HIV Antivirals Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Overall sales of HIV antivirals expanded at a CAGR of 4.0% from 2017 to 2021 owing to the rise in various government and NGO plans to offer greater accessibility to disease diagnosis and treatment for infected persons. As per Future Market Insights (FMI), the demand for HIV antivirals was approximately 66.5%, totalling US$ 44.2 Bn of the global antiviral drugs market in 2021.

For instance, the International AIDS Society (IAS) is the world’s largest association of HIV professionals from more than 170 countries. It plays a vital role in improving the lives of people with and most vulnerable to acquiring HIV by promoting the implementation of evidence-informed and human rights-based strategies.

Rising initiatives by government across the globe and NGOs is expected to boost the HIV antiviral market. Hence, key players operating in the market are capitalizing on this existing trend by launching new products.

For instance, in January 2021, ViiV Healthcare gained marketing authorization from European Commission for Tivicay (dolutegravir) for the treatment of human immunodeficiency virus (HIV-1) infection in pediatric patients.

In addition, increasing awareness about the available treatments to control HIV growth is also enhancing the demand for the HIV antivirals market.

HIV Antivirals Market Download Report Brochure

What are the Key Opportunities for Manufacturers in the HIV Antivirals Market?

Key manufacturers in HIV antivirals market are actively participating in clinical trials for the development of HIV antivirals. For instance, ViiV Healthcare is sponsoring “the study to evaluate the antiviral effect, safety and tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 infected adults”, which is currently in phase 2.

Similarly, the National Institute of Allergy and Infectious Diseases (NIAID) is also sponsoring a project named “Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents”, which is currently in phase 2. On the back of these developments, the demand in the HIV antivirals market is expected to propel over the assessment period.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Factors Restraining the Demand in HIV Antivirals Market?

The market is being impacted by limited access to HIV treatment and a lack of awareness in emerging nations. One-fifth of the urban population is HIV-positive and unaware of it. Increased HIV testing among the general population could be one way for regional and national planning actions to address this issue.

Rigorous government guidelines for the approval and commercialization of HIV drugs is also creating a hurdle for the growth of the market by limiting the number of drugs launched every year for HIV. Thus, it is harming the overall market growth.

Additionally, the lack of advanced infrastructure and limited facilities for screening and testing may limit the population with HIV infection to opt for proper treatment.

Furthermore, a large number of under-diagnosed populations is increasing due to a lack of adequate data to guide country-specific testing approaches, lack of guidelines on testing for resource-limited settings, and stigmatization of populations with or at high risk of infection.

Country-wise Insights

What Makes the U.S. the Largest Market for HIV Antivirals?

Availability of Funded Drug Assistance Programs in the U.S. to Propel Growth in HIV Antivirals Market

The U.S. dominated the North America HIV antivirals market with a total market share of around 96.8% in 2021. Demand for HIV antivirals is expected to surge due to the presence of various federally funded assistance programs in the country.

For instance, the AIDS Drug Assistance Program (ADAP) helps people with less income pay for HIV and AIDS medications. In many states, it covers extra costs such as prescription drugs and lab tests that are not for treating HIV/AIDS.

Thus, U.S. market will have a great opportunity in the region for growth, due to better assistance programs in the approaching years.

Why is the U.K. Considered a Lucrative HIV Antivirals Market in Europe?

Favorable Government and NGO Policies to Boost the U.K. HIV Antivirals Market

As per FMI, the U.K. is set to exhibit a CAGR of nearly 4.3% in the Europe HIV antivirals market during the forecast period. Government in the U.K. provides all HIV treatment free for the residents in the country, regardless of their immigration status. These kinds of facilities aid the middle and low-income population to take the best treatment for HIV.

Moreover, the approval for the use of injectable treatment using a combination of cabotegravir with rilpivirine instead of oral antiretroviral is a better treatment option for HIV patients. This is due to the dosing frequency of injectable is much lower than the oral dosage.

Will China Emerge as a Remunerative HIV Antivirals Market in East Asia?

Rising Prevalence of HIV to Improve the Demand for HIV Vaccine Boosting China HIV Antivirals Market

China held more than 75% share in the East Asia HIV antivirals market in 2021 and is projected to increase at a CAGR of 4.4% during the forecast period. Demand in the market is projected to surge on the back of rising prevalence of HIV in China.

For instance, according to studies published in NCBI, approximately 1.1 million people were living with HIV in 2020 in China. The demand for HIV antivirals is increasing with the growing rate of infection to treat or manage the disease.

How Big is the India HIV Antivirals Market?

Demand for HIV Drugs to Surge in India Amid Growing Cases of HIV and Rising Infant Mortality Rate

India held around 45.3% share in South Asia HIV antivirals market in 2021 and is projected to register a CAGR of 4.8% during the forecast period. Growth is primarily due to the high infant mortality rate and presence of HIV cases in the country.

Further, presence of awareness programs in the country, such as the National Aids Control Programme, is a key factor accelerating the demand in the market. It is a centrally sponsored scheme run by the Ministry of Health and Family Welfare of the Government of India with the goal of halving new HIV/AIDS infections and providing comprehensive care, support, and treatment to all HIV/AIDS patients.

Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Sign-Up

Category-wise Insights

Which Product Will Account for Lion’s Share in HIV Antivirals Market?

Fixed Dose Combinations (FDCs) to Account for Over 4/5th of HIV Antivirals Sales

Fixed dose combinations (FDCs) held a market share of around 83.2% in 2021 and is estimated to witness growth at a CAGR of 4.5% during the forecast period.

High demand for FDCs drugs is due to the simplicity of the regimen, drug-drug interactions, and infrequent adverse effects in combination with a low pill burden. It also prevents the virus to reproduce by restricting an enzyme HIV needs to make copies of itself.

Thus, FDCs drugs help to improve adherence to an HIV treatment regimen which drives the demand for FDCs in forthcoming years.

Which is the Leading Sales Channel in the HIV Antivirals Market?

Sales of HIV Antivirals in Hospital Pharmacies to Surge at a Robust Pace

The hospital pharmacies segment held a market share of 53.4% in 2021 and is expected to hold a share of over 54.0% in 2032.

Increasing number of people seeking treatment in hospitals are purchasing the drugs through hospital pharmacies. This is due to factors such as easy availability and subsidized prices. Thus, hospital pharmacies help in increasing the sale of HIV antiviral drugs and will drive the HIV antivirals market.

Competitive Landscape

Key players in the HIV antivirals market are concentrating on collaborations and gaining FDA approvals, as the key strategies for expanding their business in the market.

These factors will support the market players, such as Theratechnologies and AbbVie, to improve their product portfolio together with market penetration, thus, increasing their revenue share in the global market.

For instance:

In December 2021, Theratechnologies announced the submission of a license application for supplemental biologics to FDA for advancing the development of IV Push Trogarzo® for patients living with HIV.
• In March 2020, AbbVie announced a partnership with international authorities to test the efficacy of HIV medicines in treating COVID-19.

Report Scope as per HIV Antivirals Market Analysis

Attribute	Details
Market Value 2022	US$ 30.6 Bn
Market Value 2032	US$ 47.0 Bn
CAGR 2022-2032	4.4%
Forecast Period	2017-2021
Historical Data Available for	2022-2032
Market Analysis	US$ Mn for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered	US, China, Japan, Germany, Canada, UK, India, South Korea, Russia, Australia, BENELUX, Spain, Indonesia, France, Italy, Brazil, Thailand, Malaysia, Vietnam, Philippines, Mexico, GCC Countries, Argentina, South Africa, North Africa, Turkey, and New Zealand
Key Market Segments Covered	Product, Sales Channel, and Region
Key Companies Profiled	ViiV Healthcare Gilead Sciences, Inc. GlaxoSmithKline plc Merck & Co., Inc. Johnson & Johnson Genetech, Inc. Teva Pharmaceutical Industries Ltd. AbbVie Cipla Pfizer Inc. Mylan N.V. Bristol-Myers Squibb Company Boehringer Ingelheim International GmbH Macleods Pharmaceuticals Ltd Emcure Pharmaceuticals Limited Aspen Pharmacare Limited Lupin Ltd. Sun Pharmaceutical Industries Ltd. Theratechnologies Inc. Strides Arcolab Limited Hetero labs limited Laurus Laboratories Ltd

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

Fixed Dose Combinations (FDCs)
Integrase Strand Transfer Inhibitors (INSTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry Inhibitors - CCR5 co-receptor antagonist
Protease Inhibitors (PIs)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
The Middle East and Africa (MEA)

Frequently Asked Questions

How much is the HIV antivirals market worth in 2021?

The global HIV antivirals market is worth US$ 29.4 Bn in 2021 and is set to expand 1.5X over the next ten years.

What is the sales forecast for HIV antivirals through 2032?

The HIV antivirals market is expected to reach US$ 47.0 Bn by the end of 2032, with sales revenue expected to register a 4.4% CAGR over the forecast period (2022-2032).

What are the key trends shaping the HIV antivirals market?

Increasing research and development activities to develop long-acting antiviral therapies, the rising number of clinical trials, and the increasing number of product launches, are some of the key trends in this market.

Which are the top 5 countries driving demand for HIV antivirals market?

The U.S., Germany, India, China, and the U.K. are expected to drive demand for the HIV antivirals industry.

What is the North America market outlook for HIV antivirals?

North America is one of the key markets for HIV antivirals and the U.S. is accounting for around 96.8% of the North American market in the year 2021.

At what percentage is the demand for HIV antivirals expected to register growth in Europe?

The demand for HIV antivirals in Europe is expected to register a growth of 4.1% over the next ten years.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply-Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. HIV Disease Epidemiology

4.2. Regulatory Scenario

4.3. Clinical Pipeline Assessment

4.4. PESTLE Analysis

4.5. Porters Analysis

4.6. Key Promotional Strategies by Key Manufacturers

5. Market Background

5.1. Macro-Economic Factors

5.1.1. Global GDP Growth Outlook

5.1.2. Global Healthcare Spending Outlook

5.1.3. Global Antiviral Drugs Market Outlook

5.2. Forecast Factors - Relevance & Impact

5.2.1. Increasing Incidence of HIV Infection

5.2.2. Demand for HIV Medications

5.2.3. Rise in Research & Development Activities

5.2.4. Increase in Drug Approvals

5.2.5. Rising Awareness Among People

5.2.6. Rise in Use of Antivirals

5.2.7. Strategical Mergers and Acquisitions Among Key Players

5.3. Market Dynamics

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

6.1. COVID19 and Impact Analysis

6.1.1. Revenue By Product

6.1.2. Revenue By Sales Channel

6.1.3. Revenue By Country

6.2. 2021 Market Scenario

7. Global HIV Antivirals Market Demand (in Value or Size in US$ Mn) Analysis 2012–2021 and Forecast, 2022–2032

7.1. Historical Market Value (US$ Mn) Analysis, 2012–2021

7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Product

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn), By Product, 2012–2021

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032

8.3.1. Fixed Dose Combinations (FDCs)

8.3.2. Integrase Strand Transfer Inhibitors (INSTIs)

8.3.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

8.3.4. Entry Inhibitors - CCR5 co-receptor antagonist

8.3.5. Protease Inhibitors (PIs)

8.3.6. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

8.3.7. Others

8.4. Market Attractiveness Analysis By Product

9. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Sales Channel

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn), By Sales Channel, 2012–2021

9.3. Current and Future Market Size (US$ Mn) and Forecast By Sales Channel, 2022–2032

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Market Attractiveness Analysis By Sales Channel

10. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Region

10.1. Introduction

10.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021

10.3. Current and Future Market Size (US$ Mn) and Forecast By Region, 2022–2032

10.3.1. North America

10.3.2. Latin America

10.3.3. Europe

10.3.4. East Asia

10.3.5. South Asia

10.3.6. Oceania

10.3.7. Middle East and Africa (MEA)

10.4. Market Attractiveness Analysis By Region

11. North America HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

11.1. Introduction

11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

11.3.1. By Country

11.3.1.1. U.S.

11.3.1.2. Canada

11.3.2. By Product

11.3.3. By Sales Channel

11.4. Market Attractiveness Analysis

11.4.1. By Country

11.4.2. By Product

11.4.3. By Sales Channel

11.5. Market Trends

11.6. Key Market Participants - Intensity Mapping

11.7. Drivers and Restraints - Impact Analysis

11.8. Country Level Analysis & Forecast

11.8.1. U.S. HIV Antivirals Market Analysis

11.8.1.1. Introduction

11.8.1.2. Market Analysis and Forecast by Market Taxonomy

11.8.1.2.1. By Product

11.8.1.2.2. By Sales Channel

11.8.2. Canada HIV Antivirals Market Analysis

11.8.2.1. Introduction

11.8.2.2. Market Analysis and Forecast by Market Taxonomy

11.8.2.2.1. By Product

11.8.2.2.2. By Sales Channel

12. Latin America HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

12.1. Introduction

12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

12.3.1. By Country

12.3.1.1. Mexico

12.3.1.2. Brazil

12.3.1.3. Argentina

12.3.1.4. Rest of Latin America

12.3.2. By Product

12.3.3. By Sales Channel

12.4. Market Attractiveness Analysis

12.4.1. By Country

12.4.2. By Product

12.4.3. By Sales Channel

12.5. Market Trends

12.6. Key Market Participants - Intensity Mapping

12.7. Drivers and Restraints - Impact Analysis

12.8. Country Level Analysis & Forecast

12.8.1. Mexico HIV Antivirals Market Analysis

12.8.1.1. Introduction

12.8.1.2. Market Analysis and Forecast by Market Taxonomy

12.8.1.2.1. By Product

12.8.1.2.2. By Sales Channel

12.8.2. Brazil HIV Antivirals Market Analysis

12.8.2.1. Introduction

12.8.2.2. Market Analysis and Forecast by Market Taxonomy

12.8.2.2.1. By Product

12.8.2.2.2. By Sales Channel

12.8.3. Argentina HIV Antivirals Market Analysis

12.8.3.1. Introduction

12.8.3.2. Market Analysis and Forecast by Market Taxonomy

12.8.3.2.1. By Product

12.8.3.2.1.2. By Sales Channel

13. Europe HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

13.1. Introduction

13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

13.3.1. By Country

13.3.1.1. Germany

13.3.1.2. Italy

13.3.1.3. France

13.3.1.4. U.K.

13.3.1.5. Spain

13.3.1.6. BENELUX

13.3.1.7. Nordic Countries

13.3.1.8. Russia

13.3.1.9. Rest of Europe

13.3.2. By Product

13.3.3. By Sales Channel

13.4. Market Attractiveness Analysis

13.4.1. By Country

13.4.2. By Product

13.4.3. By Sales Channel

13.5. Market Trends

13.6. Key Market Participants - Intensity Mapping

13.7. Drivers and Restraints - Impact Analysis

13.8. Country Level Analysis & Forecast

13.8.1. Germany HIV Antivirals Market Analysis

13.8.1.1. Introduction

13.8.1.2. Market Analysis and Forecast by Market Taxonomy

13.8.1.2.1. By Product

13.8.1.2.2. By Sales Channel

13.8.2. Italy HIV Antivirals Market Analysis

13.8.2.1. Introduction

13.8.2.2. Market Analysis and Forecast by Market Taxonomy

13.8.2.2.1. By Product

13.8.2.2.2. By Sales Channel

13.8.3. France HIV Antivirals Market Analysis

13.8.3.1. Introduction

13.8.3.2. Market Analysis and Forecast by Market Taxonomy

13.8.3.2.1. By Product

13.8.3.2.2. By Sales Channel

13.8.4. U.K. HIV Antivirals Market Analysis

13.8.4.1. Introduction

13.8.4.2. Market Analysis and Forecast by Market Taxonomy

13.8.4.2.1. By Product

13.8.4.2.2. By Sales Channel

13.8.5. Spain HIV Antivirals Market Analysis

13.8.5.1. Introduction

13.8.5.2. Market Analysis and Forecast by Market Taxonomy

13.8.5.2.1. By Product

13.8.5.2.2. By Sales Channel

13.8.6. BENELUX HIV Antivirals Market Analysis

13.8.6.1. Introduction

13.8.6.2. Market Analysis and Forecast by Market Taxonomy

13.8.6.2.1. By Product

13.8.6.2.2. By Sales Channel

13.8.7. Nordic Countries HIV Antivirals Market Analysis

13.8.7.1. Introduction

13.8.7.2. Market Analysis and Forecast by Market Taxonomy

13.8.7.2.1. By Product

13.8.7.2.2. By Sales Channel

13.8.8. Russia HIV Antivirals Market Analysis

13.8.8.1. Introduction

13.8.8.2. Market Analysis and Forecast by Market Taxonomy

13.8.8.2.1. By Product

13.8.8.2.2. By Sales Channel

14. East Asia HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

14.1. Introduction

14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

14.3.1. By Country

14.3.1.1. China

14.3.1.2. Japan

14.3.1.3. South Korea

14.3.2. By Product

14.3.3. By Sales Channel

14.4. Market Attractiveness Analysis

14.4.1. By Country

14.4.2. By Product

14.4.3. By Sales Channel

14.5. Market Trends

14.6. Key Market Participants - Intensity Mapping

14.7. Drivers and Restraints - Impact Analysis

14.8. Country Level Analysis & Forecast

14.8.1. China HIV Antivirals Market Analysis

14.8.1.1. Introduction

14.8.1.2. Market Analysis and Forecast by Market Taxonomy

14.8.1.2.1. By Product

14.8.1.2.2. By Sales Channel

14.8.2. Japan HIV Antivirals Market Analysis

14.8.2.1. Introduction

14.8.2.2. Market Analysis and Forecast by Market Taxonomy

14.8.2.2.1. By Product

14.8.2.2.2. By Sales Channel

14.8.3. South Korea HIV Antivirals Market Analysis

14.8.3.1. Introduction

14.8.3.2. Market Analysis and Forecast by Market Taxonomy

14.8.3.2.1. By Product

14.8.3.2.2. By Sales Channel

15. South Asia HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

15.1. Introduction

15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

15.3.1. By Country

15.3.1.1. India

15.3.1.2. Indonesia

15.3.1.3. Malaysia

15.3.1.4. Philippines

15.3.1.5. Thailand

15.3.1.6. Vietnam

15.3.1.7. Rest of South Asia

15.3.2. By Product

15.3.3. By Sales Channel

15.4. Market Attractiveness Analysis

15.4.1. By Country

15.4.2. By Product

15.4.3. By Sales Channel

15.5. Market Trends

15.6. Key Market Participants - Intensity Mapping

15.7. Drivers and Restraints - Impact Analysis

15.8. Country Level Analysis & Forecast

15.8.1. India HIV Antivirals Market Analysis

15.8.1.1. Introduction

15.8.1.2. Market Analysis and Forecast by Market Taxonomy

15.8.1.2.1. By Product

15.8.1.2.2. By Sales Channel

15.8.2. Indonesia HIV Antivirals Market Analysis

15.8.2.1. Introduction

15.8.2.2. Market Analysis and Forecast by Market Taxonomy

15.8.2.2.1. By Product

15.8.2.2.2. By Sales Channel

15.8.3. Malaysia HIV Antivirals Market Analysis

15.8.3.1. Introduction

15.8.3.2. Market Analysis and Forecast by Market Taxonomy

15.8.3.2.1. By Product

15.8.3.2.2. By Sales Channel

15.8.4. Philippines HIV Antivirals Market Analysis

15.8.4.1. Introduction

15.8.4.2. Market Analysis and Forecast by Market Taxonomy

15.8.4.2.1. By Product

15.8.4.2.2. By Sales Channel

15.8.5. Thailand HIV Antivirals Market Analysis

15.8.5.1. Introduction

15.8.5.2. Market Analysis and Forecast by Market Taxonomy

15.8.5.2.1. By Product

15.8.5.2.2. By Sales Channel

15.8.6. Vietnam HIV Antivirals Market Analysis

15.8.6.1. Introduction

15.8.6.2. Market Analysis and Forecast by Market Taxonomy

15.8.6.2.1. By Product

15.8.6.2.2. By Sales Channel

16. Oceania HIV Antivirals Market 2012-2021 and Forecast 2022-2032

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

16.3.1. By Country

16.3.1.1. Australia

16.3.1.2. New Zealand

16.3.2. By Product

16.3.3. By Sales Channel

16.4. Market Attractiveness Analysis

16.4.1. By Country

16.4.2. By Product

16.4.3. By Sales Channel

16.5. Market Trends

16.6. Key Market Participants - Intensity Mapping

16.7. Drivers and Restraints - Impact Analysis

16.8. Country Level Analysis & Forecast

16.8.1. Australia HIV Antivirals Market Analysis

16.8.1.1. Introduction

16.8.1.2. Market Analysis and Forecast by Market Taxonomy

16.8.1.2.1. By Product

16.8.1.2.2. By Sales Channel

16.8.2. New Zealand HIV Antivirals Market Analysis

16.8.2.1. Introduction

16.8.2.2. Market Analysis and Forecast by Market Taxonomy

16.8.2.2.1. By Product

16.8.2.2.2. By Sales Channel

17. Middle East and Africa (MEA) HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021

17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032

17.3.1. By Country

17.3.1.1. GCC Countries

17.3.1.2. Israel

17.3.1.3. Turkey

17.3.1.4. South Africa

17.3.1.5. North Africa

17.3.1.6. Rest of Middle East and Africa

17.3.2. By Product

17.3.3. By Sales Channel

17.4. Market Attractiveness Analysis

17.4.1. By Country

17.4.2. By Product

17.4.3. By Sales Channel

17.5. Market Trends

17.6. Key Market Participants - Intensity Mapping

17.7. Drivers and Restraints - Impact Analysis

17.8. Country Level Analysis & Forecast

17.8.1. GCC Countries HIV Antivirals Market Analysis

17.8.1.1. Introduction

17.8.1.2. Market Analysis and Forecast by Market Taxonomy

17.8.1.2.1. By Product

17.8.1.2.2. By Sales Channel

17.8.2. Israel HIV Antivirals Market Analysis

17.8.2.1. Introduction

17.8.2.2. Market Analysis and Forecast by Market Taxonomy

17.8.2.2.1. By Product

17.8.2.2.2. By Sales Channel

17.8.3. Turkey HIV Antivirals Market Analysis

17.8.3.1. Introduction

17.8.3.2. Market Analysis and Forecast by Market Taxonomy

17.8.3.2.1. By Product

17.8.3.2.2. By Sales Channel

17.8.4. South Africa HIV Antivirals Market Analysis

17.8.4.1. Introduction

17.8.4.2. Market Analysis and Forecast by Market Taxonomy

17.8.4.2.1. By Product

17.8.4.2.2. By Sales Channel

17.8.5. North Africa HIV Antivirals Market Analysis

17.8.5.1. Introduction

17.8.5.2. Market Analysis and Forecast by Market Taxonomy

17.8.5.2.1. By Product

17.8.5.2.2. By Sales Channel

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies

18.2. Market Share Analysis of Top Players

18.3. Market Concentration

18.4. Market Presence Analysis

18.4.1. Regional Footprint Analysis

18.4.2. Channel Footprint Analysis

19. Competition Analysis

19.1. Competition Dashboard

19.2. Competition Benchmarking

19.3. Competition Deep Dive

19.3.1. ViiV Healthcare

19.3.1.1. Overview

19.3.1.2. Product Portfolio

19.3.1.3. Sales Footprint

19.3.1.4. Key Developments

19.3.1.5. SWOT Analysis

19.3.1.6. Strategy Overview

19.3.1.6.1. Marketing Strategies

19.3.1.6.2. Channel Strategies

19.3.2. Gilead Sciences, Inc.

19.3.2.1. Overview

19.3.2.2. Product Portfolio

19.3.2.3. Sales Footprint

19.3.2.4. Key Developments

19.3.2.5. SWOT Analysis

19.3.2.6. Strategy Overview

19.3.2.6.1. Marketing Strategies

19.3.2.6.2. Channel Strategies

19.3.3. GlaxoSmithKline plc

19.3.3.1. Overview

19.3.3.2. Product Portfolio

19.3.3.3. Sales Footprint

19.3.3.4. Key Developments

19.3.3.5. SWOT Analysis

19.3.3.6. Strategy Overview

19.3.3.6.1. Marketing Strategies

19.3.3.6.2. Channel Strategies

19.3.4. Merck & Co., Inc.

19.3.4.1. Overview

19.3.4.2. Product Portfolio

19.3.4.3. Sales Footprint

19.3.4.4. Key Developments

19.3.4.5. SWOT Analysis

19.3.4.6. Strategy Overview

19.3.4.6.1. Marketing Strategies

19.3.4.6.2. Channel Strategies

19.3.5. Johnson & Johnson

19.3.5.1. Overview

19.3.5.2. Product Portfolio

19.3.5.3. Sales Footprint

19.3.5.4. Key Developments

19.3.5.5. SWOT Analysis

19.3.5.6. Strategy Overview

19.3.5.6.1. Marketing Strategies

19.3.5.6.2. Channel Strategies

19.3.6. Genetech, Inc.

19.3.6.1. Overview

19.3.6.2. Product Portfolio

19.3.6.3. Sales Footprint

19.3.6.4. Key Developments

19.3.6.5. SWOT Analysis

19.3.6.6. Strategy Overview

19.3.6.6.1. Marketing Strategies

19.3.6.6.2. Channel Strategies

19.3.7. Teva Pharmaceutical Industries Ltd.

19.3.7.1. Overview

19.3.7.2. Product Portfolio

19.3.7.3. Sales Footprint

19.3.7.4. Key Developments

19.3.7.5. SWOT Analysis

19.3.7.6. Strategy Overview

19.3.7.6.1. Marketing Strategies

19.3.7.6.2. Channel Strategies

19.3.8. AbbVie

19.3.8.1. Overview

19.3.8.2. Product Portfolio

19.3.8.3. Sales Footprint

19.3.8.4. Key Developments

19.3.8.5. SWOT Analysis

19.3.8.6. Strategy Overview

19.3.8.6.1. Marketing Strategies

19.3.8.6.2. Channel Strategies

19.3.9. Cipla

19.3.9.1. Overview

19.3.9.2. Product Portfolio

19.3.9.3. Sales Footprint

19.3.9.4. Key Developments

19.3.9.5. SWOT Analysis

19.3.9.6. Strategy Overview

19.3.9.6.1. Marketing Strategies

19.3.9.6.2. Channel Strategies

19.3.10. Pfizer Inc.

19.3.10.1. Overview

19.3.10.2. Product Portfolio

19.3.10.3. Sales Footprint

19.3.10.4. Key Developments

19.3.10.5. SWOT Analysis

19.3.10.6. Strategy Overview

19.3.10.6.1. Marketing Strategies

19.3.10.6.2. Channel Strategies

19.3.11. Mylan N.V.

19.3.11.1. Overview

19.3.11.2. Product Portfolio

19.3.11.3. Sales Footprint

19.3.11.4. Key Developments

19.3.11.5. SWOT Analysis

19.3.11.6. Strategy Overview

19.3.11.6.1. Marketing Strategies

19.3.11.6.2. Channel Strategies

19.3.12. Bristol-Myers Squibb Company

19.3.12.1. Overview

19.3.12.2. Product Portfolio

19.3.12.3. Sales Footprint

19.3.12.4. Key Developments

19.3.12.5. SWOT Analysis

19.3.12.6. Strategy Overview

19.3.12.6.1. Marketing Strategies

19.3.12.6.2. Channel Strategies

19.3.13. Boehringer Ingelheim International GmbH

19.3.13.1. Overview

19.3.13.2. Product Portfolio

19.3.13.3. Sales Footprint

19.3.13.4. Key Developments

19.3.13.5. SWOT Analysis

19.3.13.6. Strategy Overview

19.3.13.6.1. Marketing Strategies

19.3.13.6.2. Channel Strategies

19.3.14. Macleods Pharmaceuticals Ltd

19.3.14.1. Overview

19.3.14.2. Product Portfolio

19.3.14.3. Sales Footprint

19.3.14.4. Key Developments

19.3.14.5. SWOT Analysis

19.3.14.6. Strategy Overview

19.3.14.6.1. Marketing Strategies

19.3.14.6.2. Channel Strategies

19.3.15. Emcure Pharmaceuticals Limited

19.3.15.1. Overview

19.3.15.2. Product Portfolio

19.3.15.3. Sales Footprint

19.3.15.4. Key Developments

19.3.15.5. SWOT Analysis

19.3.15.6. Strategy Overview

19.3.15.6.1. Marketing Strategies

19.3.15.6.2. Channel Strategies

19.3.16. Aspen Pharmacare Limited

19.3.16.1. Overview

19.3.16.2. Product Portfolio

19.3.16.3. Sales Footprint

19.3.16.4. Key Developments

19.3.16.5. SWOT Analysis

19.3.16.6. Strategy Overview

19.3.16.6.1. Marketing Strategies

19.3.16.6.2. Channel Strategies

19.3.17. Lupin Ltd.

19.3.17.1. Overview

19.3.17.2. Product Portfolio

19.3.17.3. Sales Footprint

19.3.17.4. Key Developments

19.3.17.5. SWOT Analysis

19.3.17.6. Strategy Overview

19.3.17.6.1. Marketing Strategies

19.3.17.6.2. Channel Strategies

19.3.18. Sun Pharmaceutical Industries Ltd.

19.3.18.1. Overview

19.3.18.2. Product Portfolio

19.3.18.3. Sales Footprint

19.3.18.4. Key Developments

19.3.18.5. SWOT Analysis

19.3.18.6. Strategy Overview

19.3.18.6.1. Marketing Strategies

19.3.18.6.2. Channel Strategies

19.3.19. Theratechnologies Inc.

19.3.19.1. Overview

19.3.19.2. Product Portfolio

19.3.19.3. Sales Footprint

19.3.19.4. Key Developments

19.3.19.5. SWOT Analysis

19.3.19.6. Strategy Overview

19.3.19.6.1. Marketing Strategies

19.3.19.6.2. Channel Strategies

19.3.20. Strides Arcolab Limited

19.3.20.1. Overview

19.3.20.2. Product Portfolio

19.3.20.3. Sales Footprint

19.3.20.4. Key Developments

19.3.20.5. SWOT Analysis

19.3.20.6. Strategy Overview

19.3.20.6.1. Marketing Strategies

19.3.20.6.2. Channel Strategies

19.3.21. Hetero labs limited

19.3.21.1. Overview

19.3.21.2. Product Portfolio

19.3.21.3. Sales Footprint

19.3.21.4. Key Developments

19.3.21.5. SWOT Analysis

19.3.21.6. Strategy Overview

19.3.21.6.1. Marketing Strategies

19.3.21.6.2. Channel Strategies

19.3.22. Laurus Laboratories Ltd

19.3.22.1. Overview

19.3.22.2. Product Portfolio

19.3.22.3. Sales Footprint

19.3.22.4. Key Developments

19.3.22.5. SWOT Analysis

19.3.22.6. Strategy Overview

19.3.22.6.1. Marketing Strategies

19.3.22.6.2. Channel Strategies

20. Assumptions and Acronyms Used

21. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

Customize Now

List of Tables

Table 1: Global HIV Antivirals Market Value (US$ Mn) Forecast by Region, 2017 & 2032

Table 2: Global HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 3: Global HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 4: North America HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 5: North America HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 6: North America HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 7: Latin America HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 8: Latin America HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 9: Latin America HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 10: Europe HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 11: Europe HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 12: Europe HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 13: East Asia HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 14: East Asia HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 15: East Asia HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 16: South Asia HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 17: South Asia HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 18: South Asia HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 19: Oceania HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 20: Oceania HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 21: Oceania HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Table 22: Middle East and Africa HIV Antivirals Market Value (US$ Mn) Forecast by Country, 2017 & 2032

Table 23: Middle East and Africa HIV Antivirals Market Value (US$ Mn) Forecast by Product, 2017 & 2032

Table 24: Middle East and Africa HIV Antivirals Market Value (US$ Mn) Forecast by Sales Channel, 2017 & 2032

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 2: Global HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 3: Global HIV Antivirals Market Value (US$ Mn) by Region, 2022 & 2032

Figure 4: Global HIV Antivirals Market Value (US$ Mn) Analysis by Region, 2017 & 2032

Figure 5: Global HIV Antivirals Market Value Share (%) and BPS Analysis by Region, 2022 & 2032

Figure 6: Global HIV Antivirals Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 8: Global HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 9: Global HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 10: Global HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 11: Global HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 12: Global HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 13: Global HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 14: Global HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 15: Global HIV Antivirals Market Attractiveness by Region, 2022-2032

Figure 16: North America HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 17: North America HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 18: North America HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 19: North America HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 20: North America HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 21: North America HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 23: North America HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 24: North America HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 25: North America HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 26: North America HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 27: North America HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 28: North America HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 29: North America HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 30: North America HIV Antivirals Market Attractiveness by Country, 2022-2032

Figure 31: Latin America HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 32: Latin America HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 33: Latin America HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 34: Latin America HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 35: Latin America HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 36: Latin America HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 38: Latin America HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 39: Latin America HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 40: Latin America HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 41: Latin America HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 42: Latin America HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 43: Latin America HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 44: Latin America HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 45: Latin America HIV Antivirals Market Attractiveness by Country, 2022-2032

Figure 46: Europe HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 47: Europe HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 48: Europe HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 49: Europe HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 50: Europe HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 51: Europe HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 53: Europe HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 54: Europe HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 55: Europe HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 56: Europe HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 57: Europe HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 58: Europe HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 59: Europe HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 60: Europe HIV Antivirals Market Attractiveness by Country, 2022-2032

Figure 61: East Asia HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 62: East Asia HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 63: East Asia HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 64: East Asia HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 65: East Asia HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 66: East Asia HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: East Asia HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 68: East Asia HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 69: East Asia HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 70: East Asia HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 71: East Asia HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 72: East Asia HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 73: East Asia HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 74: East Asia HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 75: East Asia HIV Antivirals Market Attractiveness by Country, 2022-2032

Figure 76: South Asia HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 77: South Asia HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 78: South Asia HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 79: South Asia HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 80: South Asia HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 81: South Asia HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: South Asia HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 83: South Asia HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 84: South Asia HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 85: South Asia HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 86: South Asia HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 87: South Asia HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 88: South Asia HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 89: South Asia HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 90: South Asia HIV Antivirals Market Attractiveness by Country, 2022-2032

Figure 91: Oceania HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 92: Oceania HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 93: Oceania HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 94: Oceania HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 95: Oceania HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 96: Oceania HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 97: Oceania HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 98: Oceania HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 99: Oceania HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 100: Oceania HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 101: Oceania HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 102: Oceania HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 103: Oceania HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 104: Oceania HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 105: Oceania HIV Antivirals Market Attractiveness by Country, 2022-2032

Figure 106: Middle East and Africa HIV Antivirals Market Value (US$ Mn) by Product, 2022 & 2032

Figure 107: Middle East and Africa HIV Antivirals Market Value (US$ Mn) by Sales Channel, 2022 & 2032

Figure 108: Middle East and Africa HIV Antivirals Market Value (US$ Mn) by Country, 2022 & 2032

Figure 109: Middle East and Africa HIV Antivirals Market Value (US$ Mn) Analysis by Country, 2017 & 2032

Figure 110: Middle East and Africa HIV Antivirals Market Value Share (%) and BPS Analysis by Country, 2022 & 2032

Figure 111: Middle East and Africa HIV Antivirals Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 112: Middle East and Africa HIV Antivirals Market Value (US$ Mn) Analysis by Product, 2017 & 2032

Figure 113: Middle East and Africa HIV Antivirals Market Value Share (%) and BPS Analysis by Product, 2022 & 2032

Figure 114: Middle East and Africa HIV Antivirals Market Y-o-Y Growth (%) Projections by Product, 2022-2032

Figure 115: Middle East and Africa HIV Antivirals Market Value (US$ Mn) Analysis by Sales Channel, 2017 & 2032

Figure 116: Middle East and Africa HIV Antivirals Market Value Share (%) and BPS Analysis by Sales Channel, 2022 & 2032

Figure 117: Middle East and Africa HIV Antivirals Market Y-o-Y Growth (%) Projections by Sales Channel, 2022-2032

Figure 118: Middle East and Africa HIV Antivirals Market Attractiveness by Product, 2022-2032

Figure 119: Middle East and Africa HIV Antivirals Market Attractiveness by Sales Channel, 2022-2032

Figure 120: Middle East and Africa HIV Antivirals Market Attractiveness by Country, 2022-2032